0KCC Stock Chart & Stats
$4.26
-$0.07(-1.46%)
At close: 4:00 PM EDT
$4.26
-$0.07(-1.46%)
Day’s Range― - ―
52-Week Range$2.45 - $7.77
Previous CloseN/A
Volume350.00
Average Volume (3M)678.00
Market Cap
$99.15M
Enterprise Value$200.97M
Total Cash (Recent Filing)$17.76M
Total Debt (Recent Filing)$2.63M
Price to Earnings (P/E)―
Beta0.41
Next Earnings
Nov 05, 2026EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend Yield1.14%
Share Statistics
EPS (TTM)-1.52
Shares Outstanding32,724,285
10 Day Avg. Volume596
30 Day Avg. Volume678
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)-7.26
Price to Sales (P/S)56.37
P/FCF Ratio-9.01
Enterprise Value/Market Cap2.03
Enterprise Value/Revenue120.34
Enterprise Value/Gross Profit1.08K
Enterprise Value/Ebitda-4.29
Forecast
1Y Price Target
$9.67Price Target Upside126.92% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.9
Revenue Forecast (FY)$962.80K
Bulls Say, Bears Say
Bulls Say
Expanded Medicare ReimbursementHigher covered testing frequency expands the reimbursable opportunity for the company’s transplant-monitoring products and strengthens the economic case for kitted testing. This structural reimbursement change can support broader customer adoption and improve the platform’s long-term commercial potential.
Clinical Validation And Customer EngagementReported favorable comparative data and engagement from leading transplant centers provide evidence of clinical credibility and customer interest. If sustained, this combination can reduce adoption barriers, support reference-lab partnerships, and improve the company’s position in transplant diagnostics.
Regulatory And Product Development ProgressAdvancing the FDA submission with substantially more study data improves the foundation for a potential commercial launch. Management also cites a kitted development lead versus competitors, which could support earlier market access and strengthen the company’s position if authorization is achieved.
Bears Say
Heavy And Rising Cash BurnMaterial cash consumption remains disproportionate to the current revenue base, while updated H2 guidance is above the prior run-rate expectation. Continued burn can constrain investment flexibility and increase reliance on external capital before commercial revenue becomes substantial.
Negative Stockholders’ EquityNegative equity indicates that cumulative losses have materially eroded the balance sheet and reduced financial flexibility. Even with relatively low debt, this condition can make future financing more difficult and heighten the company’s sensitivity to delays in revenue growth or regulatory progress.
Small, Declining And Unprofitable Revenue BaseThe company has not yet demonstrated durable operating leverage: revenue remains modest and declining, gross margin is low, and losses remain deep. This weak starting scale means that substantial customer adoption and reimbursement conversion are still required to support a sustainable business model.
Insight Molecular Diagnostics News
0KCC FAQ
What was Insight Molecular Diagnostics’s price range in the past 12 months?
Insight Molecular Diagnostics lowest share price was $2.45 and its highest was $7.77 in the past 12 months.
What is Insight Molecular Diagnostics’s market cap?
Insight Molecular Diagnostics’s market cap is $99.15M.
When is Insight Molecular Diagnostics’s upcoming earnings report date?
Insight Molecular Diagnostics’s upcoming earnings report date is Nov 05, 2026 which is in 13 days.
How were Insight Molecular Diagnostics’s earnings last quarter?
Insight Molecular Diagnostics released its earnings results on Aug 10, 2026. The company reported -$0.31 earnings per share for the quarter, missing the consensus estimate of -$0.254 by -$0.056.
Is Insight Molecular Diagnostics overvalued?
According to Wall Street analysts Insight Molecular Diagnostics’s price is currently Undervalued.
Does Insight Molecular Diagnostics pay dividends?
Insight Molecular Diagnostics pays a Notavailable dividend of $0.285 which represents an annual dividend yield of 1.14%. See more information on Insight Molecular Diagnostics dividends here
What is Insight Molecular Diagnostics’s EPS estimate?
Insight Molecular Diagnostics’s EPS estimate is -0.24.
How many shares outstanding does Insight Molecular Diagnostics have?
Insight Molecular Diagnostics has 32,724,285 shares outstanding.
What happened to Insight Molecular Diagnostics’s price movement after its last earnings report?
Insight Molecular Diagnostics reported an EPS of -$0.31 in its last earnings report, missing expectations of -$0.254. Following the earnings report the stock price went down -9.917%.
Which hedge fund is a major shareholder of Insight Molecular Diagnostics?
Currently, no hedge funds are holding shares in GB:0KCC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Insight Molecular Diagnostics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.67 (126.92% Upside)
$9.67 (126.92% Upside)
Blogger Sentiment
Bearish
GB:0KCC Sentiment 100%
Sector Average 66%
Sector Average 66%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-55.76%
12-Months-Change
Fundamentals
Return on Equity
271.76%
Trailing 12-Months
Asset Growth
-41.72%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Insight Molecular Diagnostics
OncoCyte Corporation functions as a molecular diagnostics firm specializing in the research, development, and market introduction of distinctive, laboratory-developed tests aimed at cancer identification. Its operations span both the United States and international territories. The company's key offerings include DetermaRx, a molecular diagnostic tool tailored for detecting early-stage adenocarcinoma of the lung, and DetermaIO, a proprietary gene expression analysis. Additionally, OncoCyte provides a range of expert services, such as biomarker discovery, assay design and refinement, and clinical trial assistance, which encompass offering various biomarker tests to pharmaceutical partners. A strategic partnership with Life Technologies Corporation focuses on the collaborative development and commercialization of the Oncomine Comprehensive Assay Plus and Determa IO assay, intended for integration with the Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was founded in 2009 and maintains its principal office in Irvine, California.
0KCC Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveys a generally positive operational and commercial outlook driven by regulatory progress (SIR meeting and tripled study samples), favorable Medicare coverage expansion (+75% surveillance tests in first 3 years), strong head-to-head clinical data and customer engagement (over half of top-10 transplant centers engaged), and a clear TAM expansion pathway. Offsetting these positives are material near-term financial risks — elevated cash burn ($10M in Q2; expected ~$8M/quarter in H2, up ~33% vs prior guidance), ongoing adjusted EBITDA losses ($7.8M) and schedule uncertainty around FDA authorization that could delay commercialization. Overall, management’s tone is constructive and forward-looking, but execution and timing risks remain important near-term considerations.View all GB:0KCC earnings summaries0KCC Stock 12 Month Forecast
Average Price Target
$9.67
▲(126.92% Upside)
Technical Analysis
Atossa Therapeutics
―
MacroGenics
―
Elutia
―
Surrozen
―
Telomir Pharmaceuticals, Inc.
―